Exhibit
4.1


 


THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED
OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY,
SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.


 


WARRANT
TO PURCHASE COMMON STOCK


 


	Company:	Corbus
    Pharmaceuticals Holdings, Inc., a Delaware
    corporation
	 	 
	Class
    of Stock:	Common
    Stock
	 	 
	Number
    of Shares:	A
    number equal to the aggregate original principal amount of the Term Loans actually funded pursuant to the Loan Agreement,
    multiplied by 3.00% divided by the Warrant Price, as in effect from time to time.
	 	 
	Warrant
    Price:	$6.96,
    subject to adjustment in accordance with the terms of Section 2
	 	 
	Issue
    Date:	[   ]
	 	 
	Expiration
    Date:	10
    years from the Issue Date
	 	 
	Loan
    Agreement:	This
    Warrant to Purchase Common Stock (“Warrant”) is issued in connection with, and as consideration of the
    commitments pursuant to, that certain Loan and Security Agreement of even date herewith among Corbus Pharmaceuticals, Inc.,
    a Delaware corporation, the Company, as a guarantor, K2 HealthVentures LLC, as administrative agent for lenders and itself
    a lender, and Ankura Trust Company, LLC, as collateral agent for lenders (as amended, restated, supplemented or otherwise
    modified from time to time, the “Loan Agreement”). Capitalized terms used herein without definition, shall
    have the meanings set forth in the Loan Agreement.


 


This
WARRANT TO PURCHASE Common STOCK certifies that, for good and valuable consideration,
K2 HEALTHVENTURES EQUITY TRUST LLC (together with any successor or permitted
assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled
to purchase the number of fully paid and non-assessable shares (the “Shares”) of the above-stated class, series
and type of stock (the “Class”) of the above-named company (the “Company”) at the above-stated
Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions
and upon the terms and conditions set forth in this Warrant. Appendix 3 sets forth, for illustrative purposes, the number
of Shares issuable pursuant to this Warrant as of the Issue Date, following the funding in full of the Second Tranche Term Loan,
and following the Third Tranche Term Loan, in each case, assuming no prior partial exercise of this Warrant and no adjustment
to the Warrant Price in accordance with the terms of Section 2.


 


Section
1. EXERCISE.


 


1.1 Method
of Exercise. Subject to Section 5.1(a), Holder may at any time and from time to time exercise this Warrant, in whole or in
part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially
the form attached hereto as Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set
forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form
of payment acceptable to the Company for the aggregate Warrant Price for the Shares being purchased.


 




    	 



     


    

 


1.2 Cashless
Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified in
Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive
Shares equal to the value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company
shall issue to Holder such number of fully paid and non-assessable Shares as are computed using the following formula:


 


X
= Y(A-B)/A


 


where:


 


		X
                                         =	the
                                         number of Shares to be issued to Holder;



 


		Y
                                         =	the
                                         number of Shares with respect to which this Warrant is being exercised (inclusive of
                                         the Shares surrendered to the Company in payment of the aggregate Warrant Price);



 


		A
                                         =	the
                                         Fair Market Value (as determined pursuant to Section 1.3 below) of one Share;
                                         and



 


		B
                                         =	the
                                         Warrant Price.



 


1.3 Fair
Market Value. For purposes of this Warrant, the “Fair Market Value” shall mean the following: If the Company’s
common stock is then traded or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter
market (a “Trading Market”), the Fair Market Value of a Share shall be the closing price or last sale price
of a share of the Company’s common stock reported for the Business Day immediately before the date on which Holder delivers
this Warrant together with its Notice of Exercise to the Company. If the Company’s common stock is not traded in a Trading
Market, the Board of Directors of the Company shall determine the Fair Market Value of a Share in its reasonable good faith judgment.


 


1.4 Delivery
of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth in Section
1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise
and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares not
so acquired.


 


1.5 Replacement
of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of
this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in
form, substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation,
the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor
and amount.


 


1.6 Treatment
of Warrant at Acquisition.


 


(a) In
the event of an Acquisition (as defined below) in which the consideration to be received by the Company’s stockholders consists
solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”),
and the Fair Market Value of one Share as determined in accordance with Section 1.3 above as of the Business Day immediately
prior to the closing date for such Cash/Public Acquisition would be greater than the Warrant Price in effect on such date, and
Holder has not exercised this Warrant pursuant to Section 1.1 above as to all Shares, then this Warrant shall automatically
be deemed to be cashless exercised pursuant to Section 1.2 above as to all Shares effective immediately prior to and contingent
upon the consummation of such Cash/Public Acquisition. In connection with such cashless exercise, Holder shall be deemed to have
restated each of the representations and warranties in Section 4 of the Warrant as the date thereof and the Company shall
promptly notify the Holder of the number of Shares (or such other securities) issued upon exercise.


 


(b) Upon
the closing of any Acquisition other than as described in subsection (a) above, the acquiring, surviving or successor entity
shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable solely for the same securities,
cash and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of this Warrant
as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time
in accordance with the provisions of this Warrant.


 




    	2



     


    

 


(c) (i)
“Acquisition” means a transaction or series of related transactions involving (A) the sale, lease, exclusive
license or other disposition of all or substantially all assets of the Company, or (B) any merger or consolidation of the Company
into or with another person or entity, or any other corporate reorganization, as a result of which the stockholders of the Company
immediately prior to such transaction own less than a majority of the Company’s (or the surviving or successor entity’s)
outstanding voting power immediately after such transaction, or (C) any sale or other transfer that results in any “person”
or “group” (within the meaning of Section 13(d) and 14(d)(2) of the Exchange Act) becoming the “beneficial owner”
(as defined in Rule 13d-3 under the Exchange Act), directly or indirectly, of a sufficient number of Equity Interests of the Company
ordinarily entitled to vote in the election of directors, empowering such “person” or “group” to elect
a majority of the members of the Board of the Company, who did not have such power before such transaction, and (ii) “Marketable
Securities” means securities meeting all of the following requirements: (i) the issuer thereof is then subject to the
reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange
Act”), and is then current in its filing of all required reports and other information under the Act and the Exchange
Act; (ii) the class and series of shares or other security of the issuer that would be received by Holder in connection with the
Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in a Trading Market, and (iii)
following the closing of such Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares
and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or convert this Warrant in
full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal
or state securities laws, rules or regulations, or (y) does not extend beyond six (6) months from the closing of such Acquisition.


 


1.7 Beneficial
Ownership. Notwithstanding anything herein to the contrary, the Company shall not be required to issue a number of Shares
upon exercise of this Warrant to the extent that, upon such issuance, the number of Shares of the Class then beneficially owned
by Holder and its Affiliates and any group of other persons or entities whose beneficial ownership of the Class would be aggregated
with Holder’s for purposes of Section 13(d) of the Exchange Act would exceed 9.985% of the total number of Shares of the
Class then issued and outstanding (the “9.985% Cap”); provided that the 9.985% Cap shall only apply to the
extent that the Common Stock is deemed to constitute an “equity security” pursuant to Rule 13d-1(i) promulgated under
the Exchange Act. For purposes of this Section 1.7, “group” has the meaning set forth in Section 13(d) of the
Exchange Act and applicable regulations of the Securities and Exchange Commission (the “Commission”), and the
percentage held by Holder shall be determined in a manner consistent with the provisions of Section 13(d) of the Exchange Act.
Upon the written request of Holder, the Company shall, within two (2) trading days, confirm to the Holder the number of shares
of the Class then outstanding. As used herein, beneficial ownership shall be determined in accordance with Section 13(d) of the
Exchange Act.


 


Section
2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.


 


2.1 Stock
Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class
payable in common stock or other securities or property (other than cash), then upon exercise of this Warrant, for each Share
acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which
Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the
Company subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number
of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If
the outstanding shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares,
the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased.


 


2.2 Reclassification,
Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are reclassified,
converted, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or
series, then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series
of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event,
and subject to further adjustment thereafter from time to time in accordance with the provisions of this Warrant. The provisions
of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations, substitutions, replacements
or other similar events.


 


2.3 No
Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the
Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional
interest by (i) the Fair Market Value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the
then-effective Warrant Price.


 




    	3



     


    

 


2.4 Notice/Certificate
as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at the Company’s
expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, class and/or
number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish Holder
with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, class and
number of Shares in effect upon the date of such adjustment.


 


Section
3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.


 


3.1 Representations
and Warranties. The Company represents and warrants to, and agrees with, Holder as follows:


 


(a) All
Shares which may be issued upon the exercise of this Warrant shall, upon issuance, be duly authorized, validly issued, fully paid
and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable
federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out
of its authorized and unissued capital stock such number of shares of the Class, as will be sufficient to permit the exercise
in full of this Warrant.


 


(b) The
issuance of this Warrant and the issuance of the Shares issuable upon exercise hereof, does not entitle any other party to exercise
preemptive rights, except to the extent waived prior to the Issue Date.


 


3.2 Notice
of Certain Events. If the Company proposes at any time to:


 


(a) declare
any dividend or distribution upon the outstanding shares of the Class, whether in cash, property, stock, or other securities and
whether or not a regular cash dividend;


 


(b) offer
for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or
series of the Company’s stock (other than pursuant to contractual pre-emptive rights);


 


(c) effect
any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Class; or


 


(d)
effect an Acquisition or to liquidate, dissolve or wind up;


 


      then,
in connection with each such event, the Company shall give Holder:


 


(1) in
the case of the matters referred to in (a) and (b) above, at least five (5) Business Days prior written notice of the earlier
to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription
rights (and specifying the date on which the holders of outstanding shares of the Class will be entitled thereto) or for determining
rights to vote, if any; and


 


(2) in
the case of the matters referred to in (c) and (d) above at least twenty (20) days prior written notice of the date when the same
will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange
their shares for the securities or other property deliverable upon the occurrence of such event and copies of all documents to
be entered into in connection with such transaction to effect the exchange and the treatment of this Warrant in connection with
such event giving rise to the notice).


 




    	4



     


    

 


If
at any time Company is not required to file financial statements and reporting with the Securities and Exchange Commission (the
‘Commission”), Company will also provide information requested by Holder that is reasonably necessary to enable
Holder to comply with Holder’s accounting or reporting requirements, including without limitation, quarterly financial statements
no later than 45 days of the end of each fiscal quarter of the Company and annual financial statements no later than 90 days of
the end of each fiscal year of Company, in each case, in the form as and when delivered to Company’s stockholders.


 


3.3 Piggyback
Registration Rights. The Company hereby agrees to grant registration rights on the terms set forth on Appendix 2
hereto.


 


Section
4. REPRESENTATIONS, WARRANTIES OF HOLDER.


 


Holder
represents and warrants to the Company as follows:


 


4.1 Purchase
for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired for
investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within
the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant
or the Shares.


 


4.2 Disclosure
of Information. Holder is aware of the Company’s business affairs and financial condition and has received or has had
full access to all the information it considers necessary or appropriate to make an informed investment decision with respect
to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and
to obtain additional information (to the extent the Company possessed such information or could acquire it without unreasonable
effort or expense) necessary to verify any information furnished to Holder or to which Holder has access.


 


4.3 Investment
Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial risk.
Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear
the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience
in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and
its underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers,
directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and
financial circumstances of such persons.


 


4.4 Accredited
Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under the Act.


 


4.5 The
Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the
Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of
Holder’s investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise
hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities
laws, or unless exemption from such registration and qualification are otherwise available. Holder is aware of the provisions
of Rule 144 promulgated under the Act.


 


4.6 No
Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights with respect to the Shares until the issuance
thereof upon exercise of this Warrant.


 


Section
5. MISCELLANEOUS.


 


5.1 Term
and Automatic Exercise Upon Expiration.


 


(a) Term.
Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time
to time on or before 6:00 PM, Pacific Time, on the Expiration Date and shall be void thereafter.


 




    	5



     


    

 


(b) Automatic
Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the Fair Market Value of one Share (or other
security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant
Price in effect on such date, then this Warrant shall automatically be deemed on and as of such date to be exercised pursuant
to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised,
and the Company shall, within a reasonable time, deliver a certificate representing the Shares (or such other securities) issued
upon such exercise to Holder.


 


5.2 Legends.
The Shares shall be imprinted with a legend in substantially the following form:


 


THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE STOCK ISSUED BY THE COMPANY TO
K2 HEALTHVENTURES EQUITY TRUST LLC DATED JULY 28, 2020 MAY NOT BE OFFERED, SOLD,
PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO
THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.


 


5.3 Compliance
with Securities Laws on Transfer. This Warrant and the Shares issuable upon exercise of this Warrant may not be transferred
or assigned in whole or in part except in compliance with applicable federal and state securities laws by the transferor and the
transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory
to the Company, as reasonably requested by the Company). The Company shall not require Holder to provide an opinion of counsel
if the transfer is to any affiliate of Holder, provided that any such transferee is an “accredited investor” as defined
in Regulation D promulgated under the Act. Additionally, the Company shall also not require an opinion of counsel if there is
no material question as to the availability of Rule 144 promulgated under the Act.


 


5.4 Transfer
Procedure. Subject to the provisions of Section 5.3 and upon providing the Company with prior written notice, K2 HealthVentures
Equity Trust Llc and any subsequent Holder may transfer all or part of this Warrant
or the Shares issuable upon exercise of this Warrant to any transferee, provided, however, in connection with any such transfer,
Holder will give the Company notice of the portion of the Warrant being transferred with the name, address and taxpayer identification
number of the transferee and Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder
if applicable); and provided further, that any subsequent transferee shall agree in writing with the Company to be bound by all
of the terms and conditions of this Warrant, and provided further, that if no Event of Default shall have occurred and be continuing,
Holder shall not transfer or assign (other than as part of an assignment of all of Holder’s rights under the Loan Agreement)
its interest in Holder’s obligations, rights, and benefits under this Warrant and the other Loan Documents to a distressed
debt fund. Notwithstanding the foregoing, (a) no part of this Warrant or the Shares issuable upon exercise of this Warrant may
be transferred except to a person named as a “Designated Holder” of K2 HealthVentures LLC in the Loan Agreement, and
(b) no part of this Warrant or the Shares issuable upon exercise of this Warrant may be transferred to a direct competitor of
the Loan Parties, whether as an operating company or direct or indirect parent with voting control over such operating company,
except in connection with an acquisition by such competitor of the Company.


 




    	6



     


    

 


5.5 Notices.
All notices and other communications hereunder from the Company to Holder, or vice versa, shall be deemed delivered and effective
(i) when given personally, (ii) on the third Business Day after being mailed by first-class registered or certified mail, postage
prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed in writing by the recipient,
or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case
at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company or such Holder
from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows
until the Company receives notice of a change of address in connection with a transfer or otherwise:


 


K2
HEALTHVENTURES LLC


855
Boylston Street, 10th Floor


Boston,
MA 02116


Attention:
Legal Notices


Email:
legal@k2hv.com; anup@k2hv.com;


derek@k2hv.com; anthony@k2hv.com


 


With
a copy to (but not constituting notice):


 


COOLEY
LLP


3175
Hanover Street


Palo
Alto, CA 94304-1150


Attention:
Cynthia Bai


Email:
cbai@cooley.com


 


Notice
to the Company shall be addressed as follows until Holder receives notice of a change in address:


 


Corbus
Pharmaceuticals Holdings, Inc.


500
River Ridge Drive


Norwood,
MA 02062


Attn:
Yuval Cohen, CEO


Email:
ycohen@corbuspharma.com


 


With
a copy, not constituting notice, to:


 


GOODWIN
PROCTER LLP


100
Northern Avenue


Boston,
MA 02210


Attention:
Milena Tantcheva


Email:
MTantcheva@goodwinlaw.com


 


5.6 Waiver.
This Warrant and any term hereof may be changed, waived, discharged or terminated (either generally or in a particular instance
and either retroactively or prospectively) only by an instrument in writing signed by the party against which enforcement of such
change, waiver, discharge or termination is sought. Notwithstanding the foregoing, the last sentence of Section 5.4 may
not be changed, waived, discharged or terminated without the express written consent of Ankura Trust Company, LLC. Ankura Trust
Company, LLC shall be a third-party beneficiary of this Warrant for purposes of enforcing the preceding sentence.


 


5.7 Counterparts;
Facsimile/Electronic Signatures. This Warrant may be executed in counterparts, all of which together shall constitute one
and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an
original signature page with regards to any agreement subject to the terms hereof or any amendment thereto.


 


5.8 Governing
Law. This Warrant shall be governed by and construed in accordance with the laws of the State of New York, without giving
effect to its principles regarding conflicts of law.


 


5.9 Headings.
The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning of any provision
of this Warrant.


 


5.10 Business
Days. “Business Day” means any day that is not a Saturday, Sunday or a day on which commercial banks in
the State of New York are required or permitted to be closed.


 


5.11 Tax
Matters. Each party hereto hereby acknowledges and agrees that each party will, upon request by the other party, provide its
determination of the fair market value of the Warrant for purposes of determining original issue discount with respect to the
investment unit comprised of the Loans and the Warrant in accordance with Sections 1272 through 1275 of the Code and Treasury
Regulations issued thereunder as promptly as practicable following such request, provided that the foregoing shall not obligate
either party to use the determination of the other party for purposes of federal income tax reporting unless otherwise required
by applicable law.


 


[Remainder
of page left blank intentionally]


 




    	7



     


    

 


[signature
page to warrant TO Purchase Common Stock]


 


IN
WITNESS WHEREOF, the parties have caused this Warrant to Purchase Common Stock to be executed by their duly authorized representatives
effective as of the Issue Date written above.


 


	company:	 
	 	 
	Corbus
    Pharmaceuticals Holdings, Inc.	 
	 	 
	By:	 	 
	Name:	Sean
    Moran	 
	Title:	Chief
    Financial Officer	 
	 	 
	HOLDER:	 
	 	 
	k2
    healthventures equity trust llc	 
	 	 
	By:	 	 
	Name:	Anup
    Arora                              	 
	Title:	Managing
    Director and Chief Information Officer	 


 




    	 



     


    

 


APPENDIX
1


 


NOTICE
OF EXERCISE


 


1.
The undersigned Holder hereby exercises its right to purchase _________________ shares of common stock of Corbus Pharmaceuticals
Holdings, Inc. (the “Company”) in accordance with the attached Warrant to Purchase Common Stock, and tenders
payment of the aggregate Warrant Price for such shares as follows:


 


[  ]
check in the amount of $________ payable to order of the Company enclosed herewith


 


[  ] Wire transfer of immediately available funds to the Company’s account


 


[  ] Cashless Exercise pursuant to Section 1.2 of the Warrant


 


[  ]
Other [Describe] __________________________________________


 


2.
Please issue a certificate or certificates representing the Shares in the name specified below:


 


	 	 	 
	 	Holder’s
    Name	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(Address)	 


 


3.
By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in
Section 4 of the Warrant to Purchase Common Stock as of the date hereof.


 


	 	HOLDER:
	 	 
	 	 
	 	 
	 	By:	                       
	 	Name:	 
	 	Title:	 
	 	 	 
	 	Date:	 


 




    	 



     


    

 


Appendix
2


 


registration
rights addendum


 


(a)
For purposes of this Addendum, the following terms shall have the meanings set forth below:


 


“Prospectus”
means the prospectus or prospectuses included in any Registration Statement, as amended or supplemented by any prospectus supplement
with respect to the terms of the offering of any portion of the Registrable Securities covered by such Registration Statement
and by all other amendments and supplements to the prospectus, including post- effective amendments and all material incorporated
by reference in such prospectus or prospectuses.


 


“Registrable
Securities” means (x) any shares of Common Stock held by any Person or issuable upon conversion, exercise or exchange
of any securities owned by any Person at any time (including the Shares exercisable upon exercise of this Warrant), and (y) any
shares of Common Stock issued or issuable with respect to any shares described in subsection (x) above by way of a stock dividend
or stock split or in connection with a combination of shares, recapitalization, merger, consolidation or other reorganization
(it being understood that for purposes of this Warrant, a Person shall be deemed to be a holder of Registrable Securities whenever
such Person has the right to then acquire or obtain from the Company any Registrable Securities, whether or not such acquisition
has actually been effected). As to any particular Registrable Securities, such securities shall cease to be Registrable Securities
when (i) a Registration Statement covering such securities has been declared effective by the Commission and such securities have
been disposed of pursuant to such effective Registration Statement, (ii) such securities are sold under circumstances in which
all of the applicable conditions of Rule 144 (or any similar provisions then in force) under the Securities Act are met, (iii)
such securities are otherwise transferred and such securities may be resold without subsequent registration under the Securities
Act, or (iv) such securities shall have ceased to be outstanding.


 


“Registration
Statement” means any registration statement of the Company which covers any of the Registrable Securities pursuant to
the provisions of this Agreement, including the Prospectus, amendments and supplements to such Registration Statement, including
post- effective amendments, all exhibits and all materials incorporated by reference in such Registration Statement.


 


(b) Whenever
the Company proposes to register any shares of its Common Stock under the Act (other than (i) a registration effected solely to
implement an employee benefit plan or a transaction to which Rule 145 of the Act is applicable, or (ii) a Registration Statement
on Form S-4, S-8 or any successor form thereto or another form not available for registering the Registrable Securities for sale
to the public) whether for its own account or for the account of one or more stockholders of the Company and the form of Registration
Statement to be used may be used for any registration of Shares (a “Piggyback Registration”), the Company shall
give prompt written notice (in any event no later than twenty (20) days prior to the filing of such Registration Statement) to
the Holder of its intention to effect such a registration and shall include in such registration all Shares with respect to which
the Company has received written requests for inclusion from the Holder within ten days after the Company’s notice has been
given to the Holder.


 


(c) If
the managing underwriter advises the Company and the Holder (if the Holder has elected to include Shares in such Piggyback Registration)
in writing that in its opinion the number of shares of Common Stock proposed to be included in such registration, including all
Registrable Securities and all other shares of Common Stock proposed to be included in such underwritten offering, exceeds the
number of shares of Common Stock which can be sold in such offering and/or that the number of shares of Common Stock proposed
to be included in any such registration would adversely affect the price per share of the Common Stock to be sold in such offering,
the Company shall include in such registration (A) first, the number of shares of Common Stock that the Company proposes to sell
(if any); (B) second, the number of shares of Common Stock requested to be included therein by the Holder; and (C) third, the
number of shares of Common Stock requested to be included therein by holders of Common Stock (other than Shares held by the Holder).


 




    	 



     


    

 


(d) If
and whenever the Holder requests that any Shares be included in a Registration Statement in accordance with subsection (a)
or (b), the Company shall use its best efforts to include the Shares in such registration in accordance with the intended
method of disposition thereof, and pursuant thereto the Company shall as soon as practicable:


 


(i) at
least five (5) Business Days before filing such Registration Statement, Prospectus or amendments or supplements thereto, furnish
to counsel of the Holder copies of such documents proposed to be filed;


 


(ii) notify
the Holder, promptly after the Company receives notice thereof, of the time when such Registration Statement has been declared
effective or a supplement to any Prospectus forming a part of such Registration Statement has been filed;


 


(iii) furnish
to the Holder such number of copies of the Prospectus included in such Registration Statement (including each preliminary Prospectus)
and any supplement thereto (in each case including all exhibits and documents incorporated by reference therein) and such other
documents as the Holder may request in order to facilitate the disposition of the Shares;


 


(iv) notify
the Holder, at any time when a Prospectus relating thereto is required to be delivered under the Act, of the happening of any
event as a result of which the Prospectus included in such Registration Statement contains an untrue statement of a material fact
or omits any fact necessary to make the statements therein not misleading, and, at the request of any such holder, the Company
shall prepare a supplement or amendment to such Prospectus so that, as thereafter delivered to the purchasers of such Shares,
such Prospectus shall not contain an untrue statement of a material fact or omit to state any fact necessary to make the statements
therein not misleading;


 


(v) use
its commercially reasonable efforts to cause such Shares to be listed on each securities exchange on which the Common Stock is
then listed;


 


(vi) in
connection with an underwritten offering, enter into such customary agreements (including underwriting and lock-up agreements
in customary form) and take all such other customary actions as the Holder or the managing underwriter of such offering request
in order to expedite or facilitate the disposition of such Shares (including, without limitation, making appropriate officers
of the Company available to participate in “road show” and other customary marketing activities, including one-on-one
meetings with prospective purchasers of the Shares);


 


(vii) otherwise
use its reasonable best efforts to comply with all applicable rules and regulations of the Commission and make available to its
stockholders an earnings statement (in a form that satisfies the provisions of Section 11(a) of the Act and Rule 158 thereunder)
no later than thirty (30) days after the end of the 12-month period beginning with the first day of the Company’s first
full fiscal quarter after the effective date of such Registration Statement, which earnings statement shall cover said 12-month
period, and which requirement will be deemed to be satisfied if the Company timely files complete and accurate information on
Forms 10-Q, 10-K and 8-K under the Exchange Act and otherwise complies with Rule 158 under the Act;


 


(viii) furnish
to the Holder and each underwriter, if any, with (i) a legal opinion of the Company’s outside counsel, dated the effective
date of such Registration Statement (and, if such registration includes an underwritten public offering, dated the date of the
closing under the underwriting agreement), in form and substance as is customarily given in opinions of the Company’s counsel
to underwriters in underwritten public offerings; and (ii) a “comfort” letter signed by the Company’s independent
certified public accountants in form and substance as is customarily given in accountants’ letters to underwriters in underwritten
public offerings;


 


(ix) without
limiting Section 5.2(f) above, use its best efforts to cause such Shares to be registered with or approved by such other
governmental agencies or authorities as may be necessary by virtue of the business and operations of the Company to enable the
Holder to consummate the disposition of such Shares in accordance with their intended method of distribution thereof;


 


(x) notify
the Holder promptly of any request by the Commission for the amending or supplementing of such Registration Statement or Prospectus
or for additional information; and


 


(xi) advise
the Holder, promptly after it shall receive notice or obtain knowledge thereof, of the issuance of any stop order by the Commission
suspending the effectiveness of such Registration Statement or the initiation or threatening of any proceeding for such purpose
and promptly use its best efforts to prevent the issuance of any stop order or to obtain its withdrawal at the earliest possible
moment if such stop order should be issued.


 




    	 



     


    

 


APPENDIX
3


 


NUMBER
OF SHARES


 


	Term Loans Funded	 	Warrant Coverage Amount (in aggregate)	 	Number of Shares Issuable (in aggregate)
	First Tranche Term Loan	 	$	600,000	 	 	 	86,206	 
	Second Tranche Term Loan	 	$	1,200,000	 	 	 	172,413	 
	Third Tranche Term Loan	 	$	1,500,000	 	 	 	215,517